Cellectar Biosciences Inc CLRB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026
Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Trading Information
- Previous Close Price
- $1.15
- Day Range
- $1.13–1.28
- 52-Week Range
- $1.11–4.70
- Bid/Ask
- $1.25 / $1.80
- Shares Outstanding
- 9.45M
- Market Cap
- $11.82M
- Volume/Avg
- 269 / 90,682
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 11
- Website
- https://www.cellectar.com
Valuation
Metric | CLRB |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.35 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CLRB
Financial Strength
Metric | CLRB |
|---|---|
Quick Ratio | 6.49 |
Current Ratio | 6.66 |
Interest Coverage | — |
Quick Ratio
CLRB
Profitability
Metric | CLRB |
|---|---|
Return on Assets (Normalized) | −115.91% |
Return on Equity (Normalized) | −196.39% |
Return on Invested Capital (Normalized) | −178.75% |
Return on Assets
CLRB
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|XXT?JG$ | LOCK|^^!T^ | $139B | |||
| Moderna Inc MRNA | LOCK|!pfff?D | LOCK|cm | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|Jj$<p?Q | LOCK|M!<P | $94B | |||
| argenx SE ADR ARGX | LOCK|Bnw#k< | LOCK|^SR | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|shwLg> | LOCK|&M | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|@&@rpXSg | LOCK|PwgCh | $30B | |||
| Incyte Corp INCY | LOCK|pMRv&Z! | LOCK|<m | $24B | |||
| BioNTech SE ADR BNTX | LOCK|lRVS?< | LOCK|X>& | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|m#D^!? | LOCK|<W>!% | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|T#KC@%> | LOCK|jn | $15B |
United States